Cargando…

Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies, Thailand

BACKGROUND: Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) help determine previous infection in individuals, regardless of whether they are asymptomatic or symptomatic. The detection of antibodies serves several purposes, including supporting other assays for disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Lerdsamran, Hatairat, Mungaomklang, Anek, Iamsirithaworn, Sopon, Prasertsopon, Jarunee, Prasert, Kriengkrai, Intalapaporn, Poj, Siriyakorn, Nirada, Wiriyarat, Witthawat, Thinpan, Nattakan, Sawadpongpan, Suteema, Sirikhetkon, Somrak, Mongkalangoon, Noparat, Petto, Suwanna, Puthavathana, Pilaipan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646009/
https://www.ncbi.nlm.nih.gov/pubmed/34872510
http://dx.doi.org/10.1186/s12879-021-06921-y
_version_ 1784610433364131840
author Lerdsamran, Hatairat
Mungaomklang, Anek
Iamsirithaworn, Sopon
Prasertsopon, Jarunee
Prasert, Kriengkrai
Intalapaporn, Poj
Siriyakorn, Nirada
Wiriyarat, Witthawat
Thinpan, Nattakan
Sawadpongpan, Suteema
Sirikhetkon, Somrak
Mongkalangoon, Noparat
Petto, Suwanna
Puthavathana, Pilaipan
author_facet Lerdsamran, Hatairat
Mungaomklang, Anek
Iamsirithaworn, Sopon
Prasertsopon, Jarunee
Prasert, Kriengkrai
Intalapaporn, Poj
Siriyakorn, Nirada
Wiriyarat, Witthawat
Thinpan, Nattakan
Sawadpongpan, Suteema
Sirikhetkon, Somrak
Mongkalangoon, Noparat
Petto, Suwanna
Puthavathana, Pilaipan
author_sort Lerdsamran, Hatairat
collection PubMed
description BACKGROUND: Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) help determine previous infection in individuals, regardless of whether they are asymptomatic or symptomatic. The detection of antibodies serves several purposes, including supporting other assays for disease diagnosis, conducting seroepidemiological studies, and evaluating vaccines. Many platforms of immunological methods for anti-SARS-CoV-2 antibody detection and their performance require validation. METHODS: This study evaluated the test performance of three autoanalyzer-based assays (Architect IgG, Vitros IgG, and Vitros total Ig) and one manual ELISA (Wantai total Ig) against a microneutralization (microNT) assay on the detection of SARS-CoV-2 antibodies. Furthermore, an indirect immunofluorescence assay verified the discordant results between the microNT and commercial assays. The test sensitivity, specificity, positive predictive value, and negative predictive value were determined based on four groups of 1005 serum samples: 102 COVID-19 prepandemic sera, 45 anti-SARS-CoV-2 positive sera, 366 sera of people at risk, and 492 sera of citizens returning from countries with a high prevalence of infection. RESULTS: The analyses as a whole showed that the performance of these commercial assays was comparable. Each group was also analysed separately to gain further insight into test performance. The Architect did not detect two positive sera of people at risk (prevalence of infection 0.55%). The other methods correctly identified these two positive sera but yielded varying false-positive results. The group of returning travellers with an infection rate of 28.3% (139 of 492) better differentiated the test performance of individual assays. CONCLUSIONS: High-throughput Architect and Vitros autoanalyzers appear appropriate for working on large sample sizes in countries that can afford the cost. The Wantai ELISA, while requiring more individual time and technical skill, may provide reliable results at a lower cost. The selection of assays will depend on the laboratory facilities and feasibility.
format Online
Article
Text
id pubmed-8646009
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86460092021-12-06 Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies, Thailand Lerdsamran, Hatairat Mungaomklang, Anek Iamsirithaworn, Sopon Prasertsopon, Jarunee Prasert, Kriengkrai Intalapaporn, Poj Siriyakorn, Nirada Wiriyarat, Witthawat Thinpan, Nattakan Sawadpongpan, Suteema Sirikhetkon, Somrak Mongkalangoon, Noparat Petto, Suwanna Puthavathana, Pilaipan BMC Infect Dis Research BACKGROUND: Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) help determine previous infection in individuals, regardless of whether they are asymptomatic or symptomatic. The detection of antibodies serves several purposes, including supporting other assays for disease diagnosis, conducting seroepidemiological studies, and evaluating vaccines. Many platforms of immunological methods for anti-SARS-CoV-2 antibody detection and their performance require validation. METHODS: This study evaluated the test performance of three autoanalyzer-based assays (Architect IgG, Vitros IgG, and Vitros total Ig) and one manual ELISA (Wantai total Ig) against a microneutralization (microNT) assay on the detection of SARS-CoV-2 antibodies. Furthermore, an indirect immunofluorescence assay verified the discordant results between the microNT and commercial assays. The test sensitivity, specificity, positive predictive value, and negative predictive value were determined based on four groups of 1005 serum samples: 102 COVID-19 prepandemic sera, 45 anti-SARS-CoV-2 positive sera, 366 sera of people at risk, and 492 sera of citizens returning from countries with a high prevalence of infection. RESULTS: The analyses as a whole showed that the performance of these commercial assays was comparable. Each group was also analysed separately to gain further insight into test performance. The Architect did not detect two positive sera of people at risk (prevalence of infection 0.55%). The other methods correctly identified these two positive sera but yielded varying false-positive results. The group of returning travellers with an infection rate of 28.3% (139 of 492) better differentiated the test performance of individual assays. CONCLUSIONS: High-throughput Architect and Vitros autoanalyzers appear appropriate for working on large sample sizes in countries that can afford the cost. The Wantai ELISA, while requiring more individual time and technical skill, may provide reliable results at a lower cost. The selection of assays will depend on the laboratory facilities and feasibility. BioMed Central 2021-12-06 /pmc/articles/PMC8646009/ /pubmed/34872510 http://dx.doi.org/10.1186/s12879-021-06921-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lerdsamran, Hatairat
Mungaomklang, Anek
Iamsirithaworn, Sopon
Prasertsopon, Jarunee
Prasert, Kriengkrai
Intalapaporn, Poj
Siriyakorn, Nirada
Wiriyarat, Witthawat
Thinpan, Nattakan
Sawadpongpan, Suteema
Sirikhetkon, Somrak
Mongkalangoon, Noparat
Petto, Suwanna
Puthavathana, Pilaipan
Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies, Thailand
title Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies, Thailand
title_full Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies, Thailand
title_fullStr Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies, Thailand
title_full_unstemmed Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies, Thailand
title_short Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies, Thailand
title_sort evaluation of different platforms for the detection of anti-sars coronavirus-2 antibodies, thailand
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646009/
https://www.ncbi.nlm.nih.gov/pubmed/34872510
http://dx.doi.org/10.1186/s12879-021-06921-y
work_keys_str_mv AT lerdsamranhatairat evaluationofdifferentplatformsforthedetectionofantisarscoronavirus2antibodiesthailand
AT mungaomklanganek evaluationofdifferentplatformsforthedetectionofantisarscoronavirus2antibodiesthailand
AT iamsirithawornsopon evaluationofdifferentplatformsforthedetectionofantisarscoronavirus2antibodiesthailand
AT prasertsoponjarunee evaluationofdifferentplatformsforthedetectionofantisarscoronavirus2antibodiesthailand
AT prasertkriengkrai evaluationofdifferentplatformsforthedetectionofantisarscoronavirus2antibodiesthailand
AT intalapapornpoj evaluationofdifferentplatformsforthedetectionofantisarscoronavirus2antibodiesthailand
AT siriyakornnirada evaluationofdifferentplatformsforthedetectionofantisarscoronavirus2antibodiesthailand
AT wiriyaratwitthawat evaluationofdifferentplatformsforthedetectionofantisarscoronavirus2antibodiesthailand
AT thinpannattakan evaluationofdifferentplatformsforthedetectionofantisarscoronavirus2antibodiesthailand
AT sawadpongpansuteema evaluationofdifferentplatformsforthedetectionofantisarscoronavirus2antibodiesthailand
AT sirikhetkonsomrak evaluationofdifferentplatformsforthedetectionofantisarscoronavirus2antibodiesthailand
AT mongkalangoonnoparat evaluationofdifferentplatformsforthedetectionofantisarscoronavirus2antibodiesthailand
AT pettosuwanna evaluationofdifferentplatformsforthedetectionofantisarscoronavirus2antibodiesthailand
AT puthavathanapilaipan evaluationofdifferentplatformsforthedetectionofantisarscoronavirus2antibodiesthailand